JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - Fusion Pharma reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Fusion Pharma announced earnings per share of $-0.550 on revenue of $166K. Analysts polled by Investing.com EPS of $-0.504 on revenue of $125K.
Fusion Pharma 's are down 27% and is trading at $2.190 , still down 74.91% from its 52 week high of $8.73 set on Wednesday, January 19, 2022.
Fusion Pharma shares gained 10.61% to trade at $2.190 in intra-day trade the report.
Fusion Pharma follows other major Healthcare sector earnings this month
Fusion Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar